Antibodies have provided invaluable treatment options for many diseases, with
immunotherapy revolutionising the treatment of several inflammatory disorders including …

Despite all of the advances in our understanding of the pathophysiology of inflammatory
bowel disease (IBD), we still do not know its cause. Some of the most recently available data …

Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being
evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable …

Introduction: The advent of tumor necrosis factor (TNF) antagonists represented a radical
change in the management of inflammatory bowel disease (IBD). Both in short-and long …

Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of
Crohn's disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and …

Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling
conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti …

Inflammatory bowel diseases (IBD) are pathological conditions characterized by chronic
inflammation that is primarily the consequence of dysregulation of the immune response …

Crohn's disease and ulcerative colitis are chronic inflammatory disorders resulting from
immune dysregulation. Patients who fail conventional medical therapy require biological …

The better understanding of the mechanisms of inflammatory bowel disease has driven our
progress intothe development of new biological therapies targeting specific molecules. Anti …

Purpose Advances in the understanding of inflammatory bowel disease (IBD)
pathophysiological mechanisms in the last few years have allowed the development of …